JCMVX
Price
$32.61
Change
-$0.00 (-0.00%)
Updated
Aug 14 closing price
Net Assets
11.45B
JVMCX
Price
$30.11
Change
+$0.03 (+0.10%)
Updated
Aug 14 closing price
Net Assets
24.41B
Interact to see
Advertisement

JCMVX vs JVMCX

JCMVX vs JVMCX Comparison Chart in %
View a ticker or compare two or three
VS
JCMVX vs. JVMCX commentary
Aug 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JCMVX is a Buy and JVMCX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JVMCX has more cash in the bank: 24.4B vs. JCMVX (11.4B). JCMVX pays higher dividends than JVMCX: JCMVX (0.26) vs JVMCX (0.00). JCMVX was incepted earlier than JVMCX: JCMVX (25 years) vs JVMCX (15 years). JVMCX (1.86) is less costly to investors than JCMVX (1.71). JVMCX is a more actively managed with annual turnover of: 48.00 vs. JCMVX (39.00). JCMVX (1000) and JVMCX (1000) have matching initial minimum investment requirements. JVMCX annual gain was more profitable for investors over the last year : 9.02 vs. JCMVX (-3.32). JVMCX return over 5 years is better than : 11.78 vs. JCMVX (-22.61).
JCMVXJVMCXJCMVX / JVMCX
Total Expense Ratio1.591.8586%
Annual Report Gross Expense Ratio1.711.8692%
Fund Existence25 years15 years-
Gain YTD16.79817.70995%
Front LoadN/AN/A-
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets11.4B24.4B47%
Annual Yield % from dividends0.260.00-
Returns for 1 year-3.329.02-37%
Returns for 3 years2.3321.7711%
Returns for 5 years-22.6111.78-192%
Returns for 10 years-4.9250.20-10%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SZCAX56.980.40
+0.71%
DWS Small Cap Core A
TSMMX20.090.12
+0.60%
Nuveen Quant Small/Mid Cap Eq Premier
GETGX51.390.14
+0.27%
Victory Sycamore Established Value R
JMNCX12.420.01
+0.08%
JPMorgan Research Market Neutral C
BSGSX16.81-0.02
-0.12%
Baird Small/Mid Cap Growth Investor